ClinicalTrials.gg
CompletedNCT07269496SQI-01-03Updated Apr 22, 2026

Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers

A Phase 1 interventional study of SQIN-Furosemide and Lasix ® Infusion in Healthy, sponsored by SQ Innovation, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by SQ Innovation, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The trial is to compare the bioavailability of the original European Lasix (furosemide injection) administered in accordance with its prescribing information with the same dose of a novel furosemide formulation developed for this subcutaneous administration. The study will also investigate PK and PD of these regimens.

Read the detailed description

This study will be an open-label, single-dose, randomized, two-way, two-period crossover study in 15 healthy adult volunteers.

Each participant will complete Screening, two Treatment phases, and Follow-up. The Screening Phase will be conducted on an outpatient basis up to 28 days prior to dosing. The Treatment Phase will comprise 2 crossover treatment periods separated by a minimum 7-day outpatient fluid re-equilibration and washout.

Participants will be admitted to the CRU on Day 1, and final eligibility assessments will be completed. Participants will be randomly assigned in a 1:1 ratio to 1 of 2 treatment sequences (AB or BA) to receive subcutaneous furosemide (Treatment A; Test) and IV furosemide (Treatment B; Reference). Participants randomized to sequence AB will receive subcutaneous furosemide for Treatment Period 1 and IV furosemide for Treatment Period 2, with treatments administered vice versa for sequence BA.

Study treatment based on the participant's assigned treatment sequence will be administered beginning in the morning of Day 1. SQIN-Furosemide will be administered by the BD Alaris™ neXus CC Syringe Pump and an infusion set programmed to delivers 30mg over first 60 minutes (total 1mL), followed by 50mg over 4 hours (total \~1.7mL), for a total dose and volume administered over 5 hours of 80mg and \~2.7mL, respectively. Furosemide Injection (20 mg/2mL) will be administered IV also with the use of the BD Alaris™ neXus CC Syringe Pump. Two doses of 40mg each will be infused at a rate of 4mg/min, such that the total amount of furosemide administered is 80 mg. PK, PD, and safety assessments will be collected over 24 hours, as detailed in the Schedule of Assessments. Participants will repeat the same procedures for Treatment Period 2 as for Treatment Period 1.

Participants will remain domiciled in the CRU through 24 hours after administration of study drug. Participants will be discharged from the CRU after all Day 2 study procedures and assessments have been completed, provided that safety parameters are acceptable to the Investigator. After the conclusion of Treatment 1 and prior to discharge, participants will be instructed regarding the diet and fluid intake, what to watch out for, how to contact study staff and when to return for Period 2. Participants will repeat the same procedures for Treatment Period 2 as for Treatment Period 1, this time receiving the alternative (cross-over) treatment.

Participants will be admitted to the CRU on the day of dosing in Treatment Period 2 and eligibility will be reconfirmed. subcutaneous or IV furosemide will then be administered on Day 9, according to the participant's randomization sequence, with PK, PD, and safety assessments collected over 24 hours, as detailed in the Schedule of Assessments.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

SQ Innovation, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Male or female ≥18 years of age
  • between 18.5 and 32.0 kg/m2 (inclusive)
  • Females will be non-pregnant and non-lactating
  • Able to participate in the study in the opinion of the Investigator
  • Has the ability to understand the requirements of the study and is willing to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  • Unable to consent to inclusion in study
  • \< 60 mL/min/1.73 m2
  • Use of diuretics
  • Systolic blood pressure (SBP) \<90 mmHg
  • Potassium \< 3.5 or > 5.3 mmol/L
  • Sodium \< 133 or > 146 mmol/L
  • Comorbidities or health issues which in the opinion of the investigator may interfere with study participation or study assessments.
  • Major surgery within 30 days prior to Screening.
  • Administration of an drug or implantation of investigational device, or participation in another interventional trial, within 30 days prior to Screening, or 5 half-lives, whichever is longer.
  • Pregnancy or breastfeeding
  • Any for furosemide administration as per furosemide SmPC
  • Any surgical or medical conditions, which in the opinion of the investigator may pose an undue risk to the participant, interfere with participation in the study or which may affect the integrity of the data
  • Any findings in Screening laboratory results which in the opinion of the investigator may pose an undue risk to the participant, interfere with participation in the study or which may affect the integrity of the data
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    SQIN-Furosemide is an investigational subcutaneous furosemide formulation at 30mg/mL

    In this study 80mg of SQIN-Furosemide will be administered subcutaneously over 5 hours using biphasic delivery profile of 30mg in the first hour and 50mg over the remaining 4 hours. IMP will be delivered by BD Alaris™ neXus CC Syringe Pump.

    Drug: SQIN-Furosemide

  • Active comparator
    Sanofi Aventis 20mg/2mL Lasix infusion

    80mg IV bolus administered over 2 doses of 40mg each for 10 mins, 2 hours apart (4mg/min).

    Drug: Lasix ® Infusion

Interventions

  • SQIN-Furosemide is a novel formulation of furosemide at 30mg/mL at pH 7.5 (range 7.1 to 7.8) intended for subcutaneous use.

    Also known as: Lasix ONYU

  • Sanofi Aventis 20mg/2mL Lasix infusion. 80mg IV bolus administered over 2 doses of 40mg each for 10 mins, 2 hours apart (4mg/min).

    Also known as: Sanofi Aventis 20mg/2mL Lasix infusion

06

What researchers measure

Primary outcomes

  1. Absolute bioavailability

    Absolute bioavailability following 5-hour subcutaneous infusion based on a comparison of AUC (subcutaneous:IV) of furosemide.

    Time frame: From enrollment to end of treatment, 30 days

Secondary outcomes

  1. Pharmacokinetic parameters - Cmax

    Maximum plasma concentration (Cmax) over the timeframe of 24 hours

    Time frame: From beginning of treatment to 24 hours post-treatment

  2. Urine volume

    Urine volume in liters

    Time frame: From beginning of treatment to 24 hours post-dose

  3. Pharmacokinetic measures - Tmax

    Time to Cmax (Tmax) over 24 hours

    Time frame: From beginning to 24 hours post-dose

  4. Pharmacokinetic measures - AUC

    Area under the concentration versus time curve (AUC) from time 0 to the last measurable plasma concentration (AUClast) and to infinity (AUCinf), half-life (t½), apparent systemic clearance and volume of distribution (subcutaneous only), and systemic clearance and volume of distribution (IV only)

    Time frame: From beginning of treatment to 24 hours post-dose

  5. Sodium concentration in urine

    Sodium concentration in urine in mmols

    Time frame: From beginning of treatment to 24 hours post-dose

07

Study locations

1 site
  • BDD Pharma
    Glasgow, Scotland G4 0SF, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Mar 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Dec 8, 2025
StartActual
Feb 9, 2026
Primary completionActual
Mar 9, 2026
CompletionActual
Mar 9, 2026
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07269496
Lead sponsor
SQ Innovation, Inc.
Collaborators
BDD Pharma Ltd
Responsible party
Sponsor
First posted
Dec 8, 2025
Start date
Feb 9, 2026
Primary completion
Mar 9, 2026
Completion
Mar 9, 2026
Last update
Apr 22, 2026

Study contacts

Lyn Cory, MD
principal investigator · BDD Pharma Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Furosemide

Start the discussion